Review
Copyright ©The Author(s) 2016.
World J Immunol. Mar 27, 2016; 6(1): 19-38
Published online Mar 27, 2016. doi: 10.5411/wji.v6.i1.19
Figure 8
Figure 8 Percent sera of MS patients treated with Betaferon, Avoex and Rebif, containing anti-IFNβ, anti-advanced glycation endproducts Abs, and responding to Advanced glycation endproducts-bovine serum albumin inhibition of binding to IFNβ. For detailed information on the experimental conditions see ref. No. 211. AGEs-BSA: Advanced glycation endproducts-bovine serum albumin.